NASDAQ:CRVS - Corvus Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.38
  • Forecasted Upside: 183.33 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.25
▲ +0.05 (2.27%)

This chart shows the closing price for CRVS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Corvus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRVS

Analyst Price Target is $6.38
▲ +183.33% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Corvus Pharmaceuticals in the last 3 months. The average price target is $6.38, with a high forecast of $8.00 and a low forecast of $3.50. The average price target represents a 183.33% upside from the last price of $2.25.

This chart shows the closing price for CRVS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Corvus Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/3/2021Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $8.00High
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$8.00High
8/3/2021Cantor FitzgeraldLower Price TargetOverweight$10.00 ➝ $5.00Medium
8/3/2021HC WainwrightReiterated RatingBuy$6.00Medium
8/3/2021MizuhoLower Price TargetNeutral$4.00 ➝ $3.50Medium
7/16/2021HC WainwrightLower Price TargetBuy$9.50 ➝ $6.00High
5/27/2021Cantor FitzgeraldInitiated CoverageOverweight$10.00High
3/26/2021HC WainwrightLower Price TargetBuy$12.00 ➝ $9.50Low
2/10/2021MizuhoDowngradeBuy ➝ Neutral$7.00 ➝ $4.00Low
11/29/2020MizuhoReiterated RatingBuy$7.00Low
10/6/2020HC WainwrightBoost Price TargetBuy$10.00 ➝ $12.00Medium
7/30/2020MizuhoReiterated RatingBuy$7.00High
5/1/2020MizuhoReiterated RatingBuy$7.00High
3/13/2020WedbushLower Price TargetOutperform$11.00 ➝ $8.00Medium
3/10/2020HC WainwrightInitiated CoverageBuy$10.00High
10/29/2019MizuhoReiterated RatingBuy$7.00Low
9/11/2019MizuhoInitiated CoverageBuy$7.00 ➝ $7.00High
5/29/2019Roth CapitalInitiated CoverageBuy ➝ Buy$5.00 ➝ $6.00Medium
3/13/2019WedbushLower Price TargetOutperform$19.00 ➝ $11.00High
11/2/2018CowenReiterated RatingBuyLow
8/15/2018Credit Suisse GroupUpgradeNeutral ➝ Buy$11.00 ➝ $15.00Low
8/8/2018WedbushReiterated RatingOutperformHigh
6/5/2018Jefferies Financial GroupInitiated CoverageBuy$17.00High
3/2/2018CowenReiterated RatingBuyLow
8/23/2017Credit Suisse GroupUpgradeUnderperform ➝ Neutral$14.00High
8/8/2017WedbushReiterated RatingOutperform$26.00Medium
8/2/2017WedbushInitiated CoverageOutperform$26.00Medium
7/4/2017Credit Suisse GroupLower Price TargetOutperform$26.00 ➝ $17.00Medium
7/4/2017CowenReiterated RatingOutperformMedium
6/6/2017CowenReiterated RatingBuyLow
5/2/2017CowenReiterated RatingBuyHigh
5/1/2017Credit Suisse GroupDowngradeNeutral ➝ Underperform$10.00High
4/6/2017Credit Suisse GroupLower Price TargetOutperform$26.00 ➝ $17.00Medium
4/6/2017CowenReiterated RatingOutperformMedium
4/5/2017Cantor FitzgeraldReiterated RatingBuy$25.00High
3/12/2017Cantor FitzgeraldReiterated RatingOverweight$23.00 ➝ $25.00High
(Data available from 1/17/2017 forward)

News Sentiment Rating

-0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/21/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/20/2021
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/19/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
11/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/18/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
1/17/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Corvus Pharmaceuticals logo
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The firm focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes B Cell Activator, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.
Read More

Today's Range

Now: $2.25
Low: $2.13
High: $2.26

50 Day Range

MA: $2.98
Low: $2.15
High: $4.77

52 Week Range

Now: $2.25
Low: $1.86
High: $9.54

Volume

351,937 shs

Average Volume

452,190 shs

Market Capitalization

$104.73 million

P/E Ratio

37.50

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Corvus Pharmaceuticals?

The following Wall Street analysts have issued reports on Corvus Pharmaceuticals in the last twelve months: Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., Mizuho, and Zacks Investment Research.
View the latest analyst ratings for CRVS.

What is the current price target for Corvus Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Corvus Pharmaceuticals in the last year. Their average twelve-month price target is $6.38, suggesting a possible upside of 183.3%. Jefferies Financial Group Inc. has the highest price target set, predicting CRVS will reach $8.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $3.50 for Corvus Pharmaceuticals in the next year.
View the latest price targets for CRVS.

What is the current consensus analyst rating for Corvus Pharmaceuticals?

Corvus Pharmaceuticals currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRVS will outperform the market and that investors should add to their positions of Corvus Pharmaceuticals.
View the latest ratings for CRVS.

What other companies compete with Corvus Pharmaceuticals?

How do I contact Corvus Pharmaceuticals' investor relations team?

Corvus Pharmaceuticals' physical mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company's listed phone number is (650) 900-4520 and its investor relations email address is [email protected] The official website for Corvus Pharmaceuticals is www.corvuspharma.com.